Novel Doublet Highly Effective in Low-Grade Serous Ovarian Cancer
The investigational combination of avutometinib (a dual RAF/MEK inhibitor) and defactinib (a FAK inhibitor) achieved very high response rates in heavily pretreated patients with recurrent